Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 390

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 390
---
604 |
| Total potentially dilutive shares      |     |     |   91,348 |     |     |   85,964 |

10. Stock-Based Compensation The Company uses equity-based compensation programs to provide long-term performance incentives for its employees, directors and consultants. These incentives consist primarily of stock options and restricted stock grants. F-51

LB Pharmaceuticals Inc Notes to Condensed Financial Statements (Unaudited) In January 2017, the Company’s Board of Directors approved the LB Pharmaceuticals Inc 2017 Stock Incentive Plan (“2017 Plan”). In October 2018, the Company’s Board of Directors approved the LB Pharmaceuticals Inc 2018 Stock Incentive Plan (“2018 Plan”). No additional shares will be issued under the 2017 and 2018 Plans. As of both June 30, 2025 and December 31, 2024, there were 0.3 million and 0.8 million shares outstanding under the 2017 Plan and the 2018 Plan, respectively. In August 2023, the Company’s Board of Directors approved the LB Pharmaceuticals Inc 2023 Stock Incentive Plan (“2023 Plan”). The 2023 Plan authorized the issuance of stock options or restricted stock up to 8.1 million shares of the Company’s common stock. In December 2024, the Company amended the 2023 Plan increasing the maximum aggregate number of shares that may be issued under the 2023 Plan to 13.0 million. The 2023 Plan expires in August 2033. As of June 30, 2025 and December 31, 2024, there were 11.9 million and 11.7 million shares outstanding under the 2023 Plan, respectively. As of June 30, 2025, 1.0 million shares were available for future issuance under the 2023 Plan. Stock Options The stock options granted in the six months ended June 30, 2025 (awarded on February 11, 2025) and 2024 vest based on one of the following schedules: (i) 25% on the first anniversary of grant date with the remaining 75% to vest in 36 equal monthly installments thereafter through the fourth anniversary of the grant date; (ii) 100% vesting in 36 equal monthly installments through the third anniversary of the grant date; or (iii) 100% vesting in 12 equal monthly installments